Evidence map›Paper›PMID 27809455›Full record

ArticleThe Korean journal of internal medicine2017

Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma.

Dae Sik Kim, Eun Sang Yu, Ka-Won Kang, Se Ryeon Lee, Yong Park, Hwa Jung Sung, Chul Won Choi, Byung Soo Kim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Korean journal of internal medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Relationship of Plasma Cell Infiltration Rates withMolecular imaging and radionuclide therapy · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dae Sik KimDivision of Oncology and Hematology, Department of Internal Medicine, Korea University School of Medicine, Seoul, Korea.
Eun Sang YuDivision of Oncology and Hematology, Department of Internal Medicine, Korea University School of Medicine, Seoul, Korea.
Ka-Won KangDivision of Oncology and Hematology, Department of Internal Medicine, Korea University School of Medicine, Seoul, Korea.
Se Ryeon LeeDivision of Oncology and Hematology, Department of Internal Medicine, Korea University School of Medicine, Seoul, Korea.
Yong ParkDivision of Oncology and Hematology, Department of Internal Medicine, Korea University School of Medicine, Seoul, Korea.
Hwa Jung SungDivision of Oncology and Hematology, Department of Internal Medicine, Korea University School of Medicine, Seoul, Korea.
Chul Won ChoiDivision of Oncology and Hematology, Department of Internal Medicine, Korea University School of Medicine, Seoul, Korea.
Byung Soo KimDivision of Oncology and Hematology, Department of Internal Medicine, Korea University School of Medicine, Seoul, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsThe aims of this study were to identify the value of inflammatory markers as pretreatment prognostic factors for patients with multiple myeloma (MM) and to estimate the value of a prognostic index including these markers at diagnosis.

methodsA total of 273 newly diagnosed MM patients undergoing active treatment were analyzed in this study. The prognostic values for survival of the pretreatment inflammatory markers were investigated. A myeloma prognostic index (MPI) was derived using prognostic factors determined to be independently significant on multivariate analysis.

resultsA high pretreatment neutrophil-lymphocyte ratio (NLR), low platelet count, and high C-reactive protein (CRP) level had independently unfavorable significance for overall survival (OS). The MPI was derived based on these factors. Per the MPI, 1 point each was assigned to high NLR, low platelet count, and high CRP. Risk categories were stratified into low- (score 0), intermediate- (score 1), and high-risk (score 2 or 3) groups. The MPI demonstrated independent statistical significance for OS on multivariate analysis ([intermediate: hazard ratio (HR), 1.91; 95% confidence interval (CI), 1.12 to 3.24] and [high: HR, 3.37; 95% CI, 2.00 to 5.69];

conclusionsThe MPI, consisting of pretreatment inflammatory markers, NLR, platelet count, and CRP, might be effective in predicting the survival of newly diagnosed MM patients undergoing active treatment.

Indexed as

Severity of Illness IndexAdultAgedAged, 80 and overC-Reactive ProteinFemaleHumansLymphocyte CountMaleMiddle AgedMultiple MyelomaPlatelet CountPrognosisRepublic of KoreaC-Reactive ProteinC-reactive proteinMultiple myelomaNeutrophil-lymphocyte ratioPlatelet countPrognosis

Identifiers

PMID27809455
PMCPMC5511937

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.